# Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy

> **NCT06942377** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 140 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Amlodipine

## Key facts

- **NCT ID:** NCT06942377
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06942377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06942377, "Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06942377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*